14 results about "Differentiation Antigens" patented technology

The present disclosure generally relates to binding agents that are capable of targeting tumor cells and immune cells. The binding agents of the present disclosure are multispecific and comprise antigen binding domains that are capable of binding to Dopamine Receptor D2 (DR2), to Programmed Cell Death Protein 1 (PD-1) and / or to Cluster of Differentiation 47 (CD47). The multispecific binding agents of the present disclosure may be used to treat subjects in need thereof.

To provide effective bispecific antibodies for use in cancer treatment.SOLUTION: Provided is a polypeptide comprising an antigen binding fragment, wherein the antigen binding fragment comprises CDR-L, CDR-H, FR-L, and FR-H, wherein the antigen binding fragment specifically binds to cluster of differentiation 3 (CD3) T cell receptor; comprises a variable heavy chain (VH) amino acid sequence having at least 90% identity to an amino acid sequence having a specific sequence; and comprises at least 99% identity or at least 90% identity to a variable light chain (VL) amino acid sequence having a specific sequence.SELECTED DRAWING: Figure 4

The invention belongs to the technical field of biomedical detection, and discloses a blood cell analysis system based on image flow cytometry, which comprises a cell staining module, the dyeing module simultaneously comprises a first fluorescent probe capable of being specifically combined with components in a cell nucleus or enriched in the cell nucleus, a second fluorescent probe capable of being specifically combined with cell nucleus DNA and a third fluorescent probe capable of being specifically combined with a blood cell differentiation antigen; an image flow cytometer; and the image processing module is used for calculating the kernel detection rate and / or the average kernel number. According to the present invention, the combination of the specific types of the cell staining dyes is adopted, the image flow cytometry is matched, and the optimized multi-dimensional fluorescence staining combination and the matched automatic image analysis process are adopted to achieve the synchronous, high-throughput and accurate quantitative analysis of the blood cell immune phenotype and the cell morphology key characteristics at the single cell level;

This invention discloses a quality control sample for flow cytometry detection of leukocyte differentiation antigen CD34 and its preparation method, relating to the field of flow cytometry quality control technology. The preparation method of this invention successfully prepared a quality control sample for flow cytometry detection of leukocyte differentiation antigen CD34. The quality control sample for flow cytometry detection of leukocyte differentiation antigen CD34 provided by this invention, as the first domestic quality control sample for CD34 flow cytometry counting, fills a gap in this product field in China. This quality control sample has performance close to imported reagents, uses the same operating method, and does not incur additional learning costs; furthermore, the product's shelf life can be stably maintained at 45–50 days, and its usage cost is far lower than imported quality control samples.

The present invention provides a method of dosing an anti-fragment crystallizable receptor-like 5 (FcRH5) / anti-cluster of differentiation 3 (CD3) bispecific antibody and lenalidomide for the treatment of cancers such as multiple myeloma.

This specification provides, in particular, an antibody-binding domain for the differentiation antigen group 3 T cell receptor (CD3), an antibody-binding domain for the epidermal growth factor receptor (EGFR), a cleavable linker sequence, and a protease-activatable bispecific fusion protein, such as a protease-activatable T cell engager, as well as therapeutic uses and methods.

The invention discloses a quality control product for flow detection of a leukocyte differentiation antigen CD34 and a preparation method, and relates to the technical field of quality control products for medical detection. According to the preparation method of the quality control product for flow cytometry of the leukocyte differentiation antigen CD34, provided by the invention, by adopting the microsphere coupled CD34 and CD45 proteins to replace genetically engineered cells and utilizing the physical stability and uniform particle size distribution of a microsphere material, the batch consistency of the quality control product is remarkably improved, and meanwhile, the efficacy period of the product is prolonged. Furthermore, in a peripheral blood treatment link, through sequence optimization of firstly fixing peripheral blood cells, then adding back plasma and finally mixing with the microspheres, stabilization of a cell membrane structure is facilitated, and release of endogenous interfering substances due to cell rupture is effectively avoided. The optimization of the sequence enables the quality control product to be closer to the real processing condition of a clinical sample, so that the specificity and the signal-to-noise ratio of a flow detection signal are improved, and the correlation between a quality control result and clinical actual detection is enhanced.

Provided is a method for treating liver cancer. The method includes administrating a therapeutic effective amount of a memory lymphocyte population to a subject in need thereof. The memory lymphocyte population contains at least one of the following marker molecules: leukocyte differentiation antigens CD3, CD4, CD8, CD16, CD56, CD62L and CD45RO.

The invention discloses a specific antibody for resisting Crassostrea gigas granulocyte membrane surface differentiation antigen protein CD22, the specific antibody is obtained by immunizing Balb / c mice by using recombinant protein of the Crassostrea gigas granulocyte membrane surface differentiation antigen protein CD22, and the recombinant protein completely contains all extracellular Ig, IGc2 and Ig-like functional domains of the Crassostrea gigas granulocyte membrane surface differentiation antigen protein CD22. The specific antibody can specifically recognize a CD22 recombinant protein with the molecular weight of 61.3 kDa and a blood lymphocyte natural protein with the molecular weight of 102.8 kDa, and it is detected that the CD22 protein is mainly expressed on cell membranes of part of agranulocytes. The specific antibody provided by the invention can be used for identifying and sorting the Crassostrea gigas CD22 + agranulocyte, and provides an important tool for deeply researching the phenotype and function of the CD22 + agranulocyte and the effect of the CD22 + agranulocyte in immune response.

This specification provides human differentiation antigen group 6 (CD6) binding molecules and nucleic acid sequences encoding such molecules. In certain embodiments, this specification provides a first single-monomer variable antibody domain (SMVAD) comprising a specific CDR and, optionally, a human CD6 binding molecule (e.g., a nanobody) having a second single-monomer variable antibody domain, and a method for treating T-cell-related diseases (e.g., cancer, e.g., T-cell lymphoma) using such molecules. In certain embodiments, the SMVAD comprises a camelid, human, or humanized framework region.

This specification provides, in particular, an antibody-binding domain for the differentiation antigen group 3 T cell receptor (CD3), an antibody-binding domain for the epidermal growth factor receptor (EGFR), a cleavable linker sequence, and a protease-activatable bispecific fusion protein, such as a protease-activatable T cell engager, as well as therapeutic uses and methods.

The present application relates to the field of vaccines, in particular to an engineered myeloid cell and a preparation method and use thereof. The present application provides an antigen-modified gel, an engineered myeloid cell and use thereof, wherein the antigen-modified gel comprises a plurality of immunostimulants and tumor antigens, attracts monocytes to migrate into and differentiate into antigen-presenting cells, and the activated and antigen-loaded monocytes further migrate out of the gel to lymph nodes, and can efficiently induce an anti-tumor immune response of lymphocytes such as T cells.

This application relates to the technical field of immunoglobulins, specifically to anti-human myeloid nuclear differentiation antigen (MNDA) monoclonal antibodies, their hybridoma cell lines, and applications. This application provides an anti-human myeloid nuclear differentiation antigen (MNDA) monoclonal antibody. At the same time, this application also provides the hybridoma cell line OTI4H6, which was deposited on November 28, 2024, at the China General Microbiological Culture Collection Center (CGMCC), and its deposit number is No. 46245. The hybridoma cell line OTI4H6 provided by this application can stably secrete an anti-human myeloid nuclear differentiation antigen (MNDA) monoclonal antibody, and can specifically bind to the MNDA protein, significantly improving the specificity, accuracy, and reliability of its immunoassay, and is applicable to the labeling of MNDA protein in tissue cells.

The present invention discloses a quality control product and a preparation method for flow cytometry detection of leukocyte differentiation antigen CD34, and relates to the technical field of quality control products for medical detection. The preparation method of the quality control product for flow cytometry detection of leukocyte differentiation antigen CD34 provided by the present invention, by adopting microspheres coupled with CD34 and CD45 proteins to replace genetically engineered cells, and utilizing the physical stability and uniform particle size distribution of the microsphere material, significantly improves the consistency of quality control products between batches, while extending the shelf life of the product. Furthermore, in the peripheral blood processing link, by optimizing the sequence of first fixing the peripheral blood cells, then adding back the plasma, and finally mixing with the microspheres, it helps to stabilize the cell membrane structure and effectively avoids cell rupture and the release of endogenous interfering substances. The optimization of this sequence makes the quality control product closer to the actual processing conditions of clinical samples, which not only improves the specificity and signal-to-noise ratio of the flow detection signal, but also enhances the correlation between the quality control results and actual clinical detection.